Expression profiling of the influence of RAS mutants on the TGFB1‐induced phenotype of the pancreatic cancer cell line PANC‐1

Expression profiling analyses were used to elucidate the functional relevance of RAS proteins in mediating the effect of TGFB1 on the transcriptional phenotype of the pancreatic cancer cell line PANC‐1. Despite the presence of one mutated KRAS2 allele in parental PANC‐1 pancreatic cancer cells, RAS‐dependent signal transduction remained susceptible to stimulation by EGF and TGFB1. To analyze the impact of RAS proteins on the TGFB1‐induced transcriptional phenotype, we used PANC‐1 cells stably transfected with a dominant negative HRAS(S17N) mutant or with a constitutively active KRAS2(G12V) mutant. TGFB1 treatment of mock‐transfected PANC‐1 cells led to an expression profile suggestive of epithelial‐mesenchymal transdifferentiation (EMT). Profiling of the HRAS(S17N)‐expressing clone demonstrated that induction of endogenous RAS activity by TGFB1 is required for the development of the TGFB1‐induced transcriptional phenotype of PANC‐1 cells. The expression of the KRAS2(G12V) mutant by itself repressed transcription of markers of epithelial differentiation and induced transcription of several extracellular matrix‐associated genes. This effect was not enhanced further by TGFB1 treatment. In contrast, transcript levels of genes associated with proliferation and cell cycle progression did not appear to be the primary targets of the synergism between the RAS‐ and TGFB1‐dependent cascades. The introduction of the dominant negative and the constitutively active RAS mutants induced partly overlapping and partly inverse effects on the TGFB1‐induced expression profile of PANC‐1 cells. Additional mechanisms such as the induction of autocrine loops and the use of different RAS isoforms or alternate, ERK‐independent signaling pathways may be involved in the interaction between the RAS‐ and the TGFB1‐dependent signaling cascades. © 2004 Wiley‐Liss, Inc.

[1]  S. Markowitz,et al.  Tumor suppressor activity of the TGF-beta pathway in human cancers. , 1996, Cytokine & growth factor reviews.

[2]  T. Seufferlein,et al.  Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. , 1999, Gastroenterology.

[3]  A. Schulze,et al.  Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. , 2000, Genes & development.

[4]  J. Bos,et al.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras , 1997, Oncogene.

[5]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[6]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[7]  R. L. Baldwin,et al.  Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. , 1993, Cancer research.

[8]  Hideji Nakamura,et al.  Hepatoma-derived Growth Factor Stimulates Cell Growth after Translocation to the Nucleus by Nuclear Localization Signals* , 2002, The Journal of Biological Chemistry.

[9]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[11]  E. Friedman,et al.  Oncogenic Ki-ras Confers a More Aggressive Colon Cancer Phenotype through Modification of Transforming Growth Factor-β Receptor III* , 2001, The Journal of Biological Chemistry.

[12]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[13]  E. Hay An overview of epithelio-mesenchymal transformation. , 1995, Acta anatomica.

[14]  J. Zavadil,et al.  Genetic programs of epithelial cell plasticity directed by transforming growth factor-β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Massagué,et al.  Controlling TGF-beta signaling. , 2000, Genes & development.

[16]  T. Seufferlein,et al.  Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. , 2001, Cancer research.

[17]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[18]  L. Feig Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases , 1999, Nature Cell Biology.

[19]  H. Friess,et al.  A pancreatic cancer-specific expression profile. , 1996, Oncogene.

[20]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[21]  G. Adler,et al.  TGFβ1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation , 2000, Oncogene.

[22]  Peter Gierschik,et al.  Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration , 2000, Oncogene.

[23]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Massagué,et al.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.

[25]  T. Gress,et al.  TGF‐β–induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase‐2 and the urokinase plasminogen activator system , 2001, International journal of cancer.

[26]  H. Friess,et al.  Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis , 1997, Genes, chromosomes & cancer.

[27]  A. Schulze,et al.  Analysis of the transcriptional program induced by Raf in epithelial cells , 2001, Nature Genetics.

[28]  K. Guan,et al.  The Dominant Negative Ras Mutant, N17Ras, Can Inhibit Signaling Independently of Blocking Ras Activation* , 2000, The Journal of Biological Chemistry.

[29]  J. Downward,et al.  Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.

[30]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[31]  J. Downward,et al.  Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. , 2002, The Journal of cell biology.

[32]  W. Birchmeier,et al.  Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells , 1993, Journal of Cell Science.

[33]  J. Massagué,et al.  Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. , 1996, Cancer surveys.

[34]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[35]  D. Botstein,et al.  The transcriptional program in the response of human fibroblasts to serum. , 1999, Science.

[36]  D. Welch Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential , 1990 .

[37]  E. Friedman,et al.  Transforming Growth Factor β1 Induces Proliferation in Colon Carcinoma Cells by Ras-dependent, smad-independent Down-regulation of p21cip1* , 2002, The Journal of Biological Chemistry.

[38]  M. Korc,et al.  Role of growth factors in pancreatic cancer. , 1998, Surgical oncology clinics of North America.

[39]  K. M. Mulder,et al.  Transforming Growth Factor β Activation of p44mapk in Proliferating Cultures of Epithelial Cells (*) , 1995, The Journal of Biological Chemistry.